Evercore ISI raised the firm’s price target on CVS Health (CVS) to $65 from $60 and keeps an Outperform rating on the shares. Given 2025 will “likely be a year of stabilization-to-some-improvement” for the Health Care Benefits segment of CVS Health, the firm sees 2026 being “a major inflection point in performance,” with potentially more upside to its revised estimates, the analyst tells investors.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CVS:
- FTC Slams UnitedHealth (NYSE:UNH), CVS and Cigna PBMs for Inflating Prices by $7.3B
- FTC says ‘Big 3 PBMs’ marked up generic drugs by thousands of percent
- CMS expects 4.33% increase in Medicare Advantage rates in 2026
- CMS likely to release 2026 MA rates Friday, says Wolfe Research
- CVS Health call volume above normal and directionally bullish